RxDoctor Payments Data

Carole Moodhe, MD

Internal Medicine · New Hyde Park, NYNPI 1659440170

Payments from drug & device makers

$2,164in general payments, 2019–2025

Across 62 payments — averaging $34.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$353
  • Novartis$203
  • Abbott$164
  • Pfizer$127
  • Merck$110
  • plus $196 from 5 others

What the payments were for

  • Food & beverage$2,164100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk33$1,011
Amgen(2 entities)7$353
Novartis6$203
Abbott2$164
Pfizer2$127
Merck2$110
GSK5$106
Lilly USA, LLC2$34
AbbVie1$20
Almatica Pharma LLC1$18
AstraZeneca1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,164 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$212,457
Medicare patients
199
Services billed
4,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$35,446
EliquisApixaban30$20,582
JanuviaSitagliptin Phosphate13$14,731
VascepaIcosapent Ethyl12$12,783
Rosuvastatin Calcium374$6,111
Tresiba Flextouch U-100Insulin Degludec12$6,005
Diclofenac Sodium17$3,434
SynthroidLevothyroxine Sodium43$3,145
Omega-3 Acid Ethyl Esters33$2,855
Ezetimibe71$2,402
Losartan Potassium187$2,162
Levothyroxine Sodium117$2,082
Amlodipine Besylate249$1,469
Metoprolol Succinate73$1,263
Chlorthalidone52$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,011$35,44632 claims
PfizerEliquis$127$20,58230 claims
MerckJanuvia$110$14,73113 claims
AbbVieSynthroid$20$3,14543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →